Paper Details

  1. Home
  2. Paper Details

Phase 1 and pharmacodynamic trial of everolimus in combination with cetuximab in patients with advanced cancer.

Author: AvadhaniAnjali N, CiunciChristine A, DivgiChaitanya R, EnglanderSarah, FlahertyKeith T, GiantonioBruce J, HarlackerKathleen, KangHyunseon C, O'DwyerPeter J, PeriniRodolfo F, RedlingerMaryann, RosenMark A, SchnallMitchell, SongHee Kwon, SunWeijing, TroxelAndrea

Clinical Trial, Phase IThe first stage of clinical trials in humans. Evaluates the safety, tolerability, and pharmacokinetics of a new drug/treatment.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Everolimus and cetuximab can be safely administered together at standard doses and are associated with prolonged disease control. The recommended dose for Phase 2 trials is 70 mg of oral everolimus weekly in combination with standard cetuximab. Imaging studies indicate that metabolic inhibition by everolimus alone and in combination with cetuximab predominates over changes in tumor perfusion in this patient population.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Preclinical and clinical studies suggest mTOR (mammalian target of rapamycin) inhibitors may have metabolic and antiangiogenic effects, and synergize with epidermal growth factor pathway inhibitors. Therefore, a phase 1/pharmacodynamic trial of everolimus with cetuximab was performed. M...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1002/cncr.28294

データ提供：米国国立医学図書館（NLM）

Everolimus and Cetuximab: A New Path in the Desert of Cancer Treatment

The desert of cancer treatment is a vast and unforgiving landscape, demanding innovative approaches to manage advanced cancers. This phase 1/pharmacodynamic trial investigates the combination of everolimus, an mTOR inhibitor, and cetuximab, an epidermal growth factor pathway inhibitor, in patients with advanced cancer. The authors conducted a dose-escalation study to determine the safety and efficacy of this combination therapy. The results showed that everolimus and cetuximab were well-tolerated at standard doses, with an expected toxicity profile. The study also demonstrated that everolimus and cetuximab in combination could achieve prolonged disease control in some patients, providing a potential new avenue for managing advanced cancers.

Everolimus and Cetuximab: A Promising Oasis in the Desert of Cancer Treatment

The research findings suggest that everolimus and cetuximab in combination may offer a promising treatment option for advanced cancers. This discovery, like a refreshing oasis in the desert, offers hope for individuals seeking effective and well-tolerated treatment strategies.

Navigating the Desert of Cancer Treatment: Everolimus and Cetuximab

Everolimus and cetuximab in combination, like a well-charted path through the desert, may offer a new and potentially effective treatment option for advanced cancers. This research highlights the importance of exploring novel combination therapies to improve patient outcomes and enhance the fight against cancer.

Dr.Camel's Conclusion

This phase 1/pharmacodynamic trial explores the combination of everolimus and cetuximab in patients with advanced cancer. The findings suggest that this combination therapy can be safely administered at standard doses and may offer a promising treatment option for managing advanced cancers. This research provides valuable insights into the potential benefits of combining targeted therapies to enhance the fight against cancer.

Date :
  1. Date Completed 2014-05-13
  2. Date Revised 2021-12-03
Further Info :

Pubmed ID

24108668

DOI: Digital Object Identifier

10.1002/cncr.28294

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.